论文部分内容阅读
骨髓增殖性肿瘤(MPNs)是一类造血干细胞起源的骨髓克隆性疾病,是一种恶性血液系统疾病〔1〕。2008年,WHO论述的MPNs的详细列表包括慢性粒细胞白血病(CML),真性红细胞增多症(PV),原发性血小板增多症(ET),原发性骨髓纤维化(PMF),慢性中性粒细胞白血病(CNL),慢性嗜酸性粒细胞白血病/高嗜酸性粒细胞综合症(CEL/HES)和肥大细胞病(MCD)等疾病,并将有无JAK2突变列为重要的诊断标准〔2〕。近年来,JAK2激酶抑制剂对MPNs治疗的研究为MPNs患者带来了新的希望,也为临床使用JAK2V617F突变的基因靶向治疗提供了较好的实验依据。本文就至今为止JAK2V617F突变及JAK2激酶抑制剂对
Myeloproliferative neoplasms (MPNs) are a type of hematopoietic stem cell origin bone marrow disease, is a malignant hematological system [1]. A detailed list of the MPNs discussed by WHO in 2008 included chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), chronic neutral And myeloid leukemia (CNL), chronic eosinophilic leukemia / hypereosinophilic syndrome (CEL / HES) and mast cell disease (MCD) and other diseases, and the presence or absence of JAK2 mutations as an important diagnostic criteria [2 ]. In recent years, JAK2 kinase inhibitors on MPNs treatment of MPNs in patients with new hope, but also for the clinical use of JAK2V617F gene mutation targeted therapy provides a good experimental basis. This article so far JAK2V617F mutation and JAK2 kinase inhibitor pairs